A Phase I Study of EKB-569 in Combination with Capecitabine in Patients with Advanced Colorectal Cancer
PURPOSE: To determine the maximum tolerated dose (MTD), characterize the principal toxicities, and assess the pharmacokinetics of EKB-569, an oral selective irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with capecitabine in patients with advanced colo...
Na minha lista:
Main Authors: | , , , , , , , , , , , , , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
2008
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3086427/ https://ncbi.nlm.nih.gov/pubmed/18765554 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0433 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|